医学
立场声明
流行病学
怀孕
妊娠高血压
重症监护医学
疾病
介绍(产科)
妊娠高血压
临床流行病学
产科
原发性高血压
儿科
家庭医学
内分泌学
血压
内科学
子痫前期
生物
遗传学
作者
Costas Thomopoulos,Jana Brguljan Hitij,Tine De Backer,Εugenia Gkaliagkousi,Reinhold Kreutz,Marilucy Lopez‐Sublet,Maria Marketou,Anastasia S. Mihailidou,Agnieszka Olszanecka,Antoinette Péchère-Bertschi,Mariana Paula Pérez,Alexandre Persu,Federica Piani,Thenral Socrates,Katarzyna Stolarz‐Skrzypek,Renata Cífková
标识
DOI:10.1097/hjh.0000000000003739
摘要
Hypertensive disorders in pregnancy (HDP), remain the leading cause of adverse maternal, fetal, and neonatal outcomes. Epidemiological factors, comorbidities, assisted reproduction techniques, placental disorders, and genetic predisposition determine the burden of the disease. The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed clinical trials in the field explain the absence of consensus on disease management among relevant international societies. Thus, the usual clinical management of HDP is largely empirical. The current position statement of the Working Group ‘Hypertension in Women’ of the European Society of Hypertension (ESH) aims to employ the current evidence for the management of HDP, discuss the recommendations made in the 2023 ESH guidelines for the management of hypertension, and shed light on controversial issues in the field to stimulate future research.
科研通智能强力驱动
Strongly Powered by AbleSci AI